BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1062 related articles for article (PubMed ID: 18801058)

  • 21. The detection of wt-1 transcripts is not associated with an increased leukemic relapse rate in patients with acute leukemia after allogeneic bone marrow or peripheral blood stem cell transplantation.
    Elmaagacli AH; Beelen DW; Trenschel R; Schaefer UW
    Bone Marrow Transplant; 2000 Jan; 25(1):91-6. PubMed ID: 10654021
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Wilms' tumor gene 1 transcript levels in leukapheresis of peripheral blood hematopoietic cells predict relapse risk in patients autografted for acute myeloid leukemia.
    Messina C; Candoni A; Carrabba MG; Tresoldi C; Sala E; Tassara M; Crippa A; Peccatori J; Assanelli A; Gattillo S; Bellio L; Fanin R; Ciceri F; Bernardi M
    Biol Blood Marrow Transplant; 2014 Oct; 20(10):1586-91. PubMed ID: 24954546
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison between multiparameter flow cytometry and WT1-RNA quantification in monitoring minimal residual disease in acute myeloid leukemia without specific molecular targets.
    Rossi G; Minervini MM; Carella AM; de Waure C; di Nardo F; Melillo L; D'Arena G; Zini G; Cascavilla N
    Leuk Res; 2012 Apr; 36(4):401-6. PubMed ID: 22196957
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party.
    Schmid C; Labopin M; Nagler A; Bornhäuser M; Finke J; Fassas A; Volin L; Gürman G; Maertens J; Bordigoni P; Holler E; Ehninger G; Polge E; Gorin NC; Kolb HJ; Rocha V;
    J Clin Oncol; 2007 Nov; 25(31):4938-45. PubMed ID: 17909197
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Quantitative monitoring of NPM1 mutations provides a valid minimal residual disease parameter following allogeneic stem cell transplantation.
    Bacher U; Badbaran A; Fehse B; Zabelina T; Zander AR; Kröger N
    Exp Hematol; 2009 Jan; 37(1):135-42. PubMed ID: 19100523
    [TBL] [Abstract][Full Text] [Related]  

  • 26. WT1 gene expression: an excellent tool for monitoring minimal residual disease in 70% of acute myeloid leukaemia patients - results from a single-centre study.
    Østergaard M; Olesen LH; Hasle H; Kjeldsen E; Hokland P
    Br J Haematol; 2004 Jun; 125(5):590-600. PubMed ID: 15147374
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Elevated levels of WT1 transcripts in bone marrow harvests are associated with a high relapse risk in patients autografted for acute myeloid leukaemia.
    Osborne D; Frost L; Tobal K; Liu Yin JA
    Bone Marrow Transplant; 2005 Jul; 36(1):67-70. PubMed ID: 15908982
    [TBL] [Abstract][Full Text] [Related]  

  • 28. WT1 Measurable Residual Disease Assay in Patients With Acute Myeloid Leukemia Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation: Optimal Time Points, Thresholds, and Candidates.
    Cho BS; Min GJ; Park SS; Shin SH; Yahng SA; Jeon YW; Yoon JH; Lee SE; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Kim M; Kim Y; Kim HJ
    Biol Blood Marrow Transplant; 2019 Oct; 25(10):1925-1932. PubMed ID: 31173897
    [TBL] [Abstract][Full Text] [Related]  

  • 29. WT1 Expression in Circulating RNA as a Minimal Residual Disease Marker for AML Patients After Stem-Cell Transplantation.
    Zhong L; Wei L; Chen J; Huang X; Gong Y; Lu Y
    Mol Diagn Ther; 2015 Aug; 19(4):205-12. PubMed ID: 26138637
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Significance of monitoring WT1 mRNA levels of peripheral blood and bone marrow in acute myeloid leukemia].
    Kitamura K; Nakano Y; Watamoto K; Koga D; Naoe T
    Rinsho Ketsueki; 2010 Dec; 51(12):1748-55. PubMed ID: 21258184
    [TBL] [Abstract][Full Text] [Related]  

  • 31. BAALC and WT1 expressions from diagnosis to hematopoietic stem cell transplantation: consecutive monitoring in adult patients with core-binding-factor-positive AML.
    Yoon JH; Kim HJ; Shin SH; Yahng SA; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS; Park CW; Lim JH
    Eur J Haematol; 2013 Aug; 91(2):112-21. PubMed ID: 23672350
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictive value of pretransplantation molecular minimal residual disease assessment by WT1 gene expression in FLT3-positive acute myeloid leukemia.
    Candoni A; De Marchi F; Zanini F; Zannier ME; Simeone E; Toffoletti E; Chiarvesio A; Cerno M; Filì C; Patriarca F; Fanin R
    Exp Hematol; 2017 May; 49():25-33. PubMed ID: 28159598
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic impact of RT-PCR-based quantification of WT1 gene expression during MRD monitoring of acute myeloid leukemia.
    Weisser M; Kern W; Rauhut S; Schoch C; Hiddemann W; Haferlach T; Schnittger S
    Leukemia; 2005 Aug; 19(8):1416-23. PubMed ID: 15920493
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Monitoring bcr-abl mRNA levels by real-time quantitative RT-PCR in chronic myeloid leukemia patients after hematopoietic stem cell transplantation].
    Qin YZ; Li JL; Zhu HH; Ruan GR; Li LD; Zhang Y; Xu LP; Liu DH; Liu YR; Huang XJ; Chen SS; Lu DP
    Zhonghua Xue Ye Xue Za Zhi; 2006 Aug; 27(8):511-4. PubMed ID: 17172121
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic implications of Wilms' tumor gene (WT1) expression in patients with de novo acute myeloid leukemia.
    Barragán E; Cervera J; Bolufer P; Ballester S; Martín G; Fernández P; Collado R; Sayas MJ; Sanz MA
    Haematologica; 2004 Aug; 89(8):926-33. PubMed ID: 15339675
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High WT1 expression after induction therapy predicts high risk of relapse and death in pediatric acute myeloid leukemia.
    Lapillonne H; Renneville A; Auvrignon A; Flamant C; Blaise A; Perot C; Lai JL; Ballerini P; Mazingue F; Fasola S; Dehée A; Bellman F; Adam M; Labopin M; Douay L; Leverger G; Preudhomme C; Landman-Parker J
    J Clin Oncol; 2006 Apr; 24(10):1507-15. PubMed ID: 16575000
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Successful donor leukocyte transfusion at molecular relapse for a patient with acute myeloid leukemia who was treated with allogenic bone marrow transplantation: importance of the monitoring of minimal residual disease by WT1 assay.
    Ogawa H; Tsuboi A; Oji Y; Tamaki H; Soma T; Inoue K; Sugiyama H
    Bone Marrow Transplant; 1998 Mar; 21(5):525-7. PubMed ID: 9535047
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Low WT1 transcript levels at diagnosis predicted poor outcomes of acute myeloid leukemia patients with t(8;21) who received chemotherapy or allogeneic hematopoietic stem cell transplantation.
    Qin YZ; Wang Y; Zhu HH; Gale RP; Zhang MJ; Jiang Q; Jiang H; Xu LP; Chen H; Zhang XH; Liu YR; Lai YY; Jiang B; Liu KY; Huang XJ
    Chin J Cancer; 2016 May; 35():46. PubMed ID: 27197573
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Correlation of minimal residual disease by assessing Wilms tumor gene expression and engraftment by variable number of tandem repeats in children with leukemia posthematopoietic stem cell transplantation.
    Olszewski M; Chou PM; Huang W; Tallman S; Kletzel M
    Pediatr Dev Pathol; 2006; 9(3):203-9. PubMed ID: 16944968
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Leukaemia relapse after allogeneic transplants for acute myeloid leukaemia: predictive role of WT1 expression.
    Pozzi S; Geroldi S; Tedone E; Luchetti S; Grasso R; Colombo N; Di Grazia C; Lamparelli T; Gualandi F; Ibatici A; Bregante S; Van Lint MT; Raiola AM; Dominietto A; Varaldo R; Signori A; Bacigalupo A
    Br J Haematol; 2013 Feb; 160(4):503-9. PubMed ID: 23294252
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 54.